Regarding the bioactivity on NASH, studies either from transgenic mice or treatment with FGF19 protein have shown that FGF19 alleviates lipid accumulation in the liver and thereby prevents NASH 20, 41, 42. The gene discussed is FGF19; the disease is metabolic dysfunction-associated steatohepatitis.